Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.34 USD
−110.78 M USD
0.00 USD
104.37 M
About Humacyte, Inc.
Sector
Industry
CEO
Laura E. Niklason
Website
Headquarters
Durham
Founded
2004
FIGI
BBG00XPPT7S7
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.
$$HUMA BUYING signals? Currently, Huma is trading below its value and presents an opportunity for immediate increase in the near future. Based on the charts, a target price of $13 is suggested. Long-term holding strategy is recommended.
Humacyte, bull case.. my speculation.. If if if... Humacyte can sell 1000-3000 symvess annually Marketcap going to be 5-15billion :)
Currently below 700million
Im bias and huma is 30% of my stockportfolio
Humacyte lawsuite is questionableAs a scientist, I have been in medical device development and manufacturing. Every company faces ups and downs in manufacturing medical devices. FDA regularly visits those companies for audits. As an investor, I hired and a FDA compliance expert about two weeks ago to analyze the FDA findings and de
They call me Pablo picassoJust some lines and indicators around this stock after pipers event that was surprisingly positive.. still DCA if drops to 3,80 after that i would own more then 3.5k shares.
Im a shrimp in the space but need to start somewhere
FDA APROVAL HUMA had a significant decline with DELAY in approval over something minor, still waiting see if it holds the 100MA and gets approval. ANALSYTS PREDICT 11$
Some insider selling and possible dilution. Watching 👀
The storyline of Humacyte.. its "imminent" We are at pessimistic phase. Insiders selling etc. That only sell 20-30% of shares after a x2-3 run up. Consilidation.. drop at delay.. no clear answer FDA... Conference calls say answer in 2025.. approval is imminent (see minds) only question.. wil we get approval after 10months(so initial time app
Possible breakout of HUMA with strong upside potentialDaily timeframe bull flag with strong potential for a breakout. Measured move from point of breakout puts it at possible ATH territory?!
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of HUMA is 5.21 USD — it has decreased by −3.82% in the past 24 hours. Watch Humacyte, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Humacyte, Inc. stocks are traded under the ticker HUMA.
HUMA stock has risen by 7.96% compared to the previous week, the month change is a 19.14% rise, over the last year Humacyte, Inc. has showed a 80.78% increase.
We've gathered analysts' opinions on Humacyte, Inc. future price: according to them, HUMA price has a max estimate of 25.00 USD and a min estimate of 6.00 USD. Watch HUMA chart and read a more detailed Humacyte, Inc. stock forecast: see what analysts think of Humacyte, Inc. and suggest that you do with its stocks.
HUMA reached its all-time high on Sep 1, 2021 with the price of 17.45 USD, and its all-time low was 1.96 USD and was reached on Dec 30, 2022. View more price dynamics on HUMA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
HUMA stock is 7.42% volatile and has beta coefficient of 0.32. Track Humacyte, Inc. stock price on the chart and check out the list of the most volatile stocks — is Humacyte, Inc. there?
Today Humacyte, Inc. has the market capitalization of 707.67 M, it has increased by 27.40% over the last week.
Yes, you can track Humacyte, Inc. financials in yearly and quarterly reports right on TradingView.
Humacyte, Inc. is going to release the next earnings report on Mar 21, 2025. Keep track of upcoming events with our Earnings Calendar.
HUMA earnings for the last quarter are −0.33 USD per share, whereas the estimation was −0.25 USD resulting in a −32.45% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Humacyte, Inc. earnings.
Humacyte, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
HUMA net income for the last quarter is −39.20 M USD, while the quarter before that showed −56.66 M USD of net income which accounts for 30.82% change. Track more Humacyte, Inc. financial stats to get the full picture.
No, HUMA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 183.00 employees. See our rating of the largest employees — is Humacyte, Inc. on this list?
Like other stocks, HUMA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Humacyte, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Humacyte, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Humacyte, Inc. stock shows the buy signal. See more of Humacyte, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.